GPR116 Lentiviral Activation Particles (h): sc-408424-LAC
- Target species: human
- 200 µl of transduction-ready, high-titer CRISPR/dCas9 Lentiviral Activation Particles
- GPR116 Lentiviral Activation Particles (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically and efficiently upregulate gene expression via lentiviral transduction of cells
- GPR116 Lentiviral Activation Particles (h) contain the following SAM Activation elements: a deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, an MS2-p65-HSF1 fusion protein and a target-specific 20 nt guide RNA. They also contain the blasticidin, hygromycin and puromycin resistance genes
- Upon transduction, the SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by GPR116 Lentiviral Activation Plasmid (h) and GPR116 Lentiviral Activation Plasmid (h2) target distinct regulatory regions of the ADGRF5 promoter. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GPR116 Lentiviral Activation Particles (h) | sc-408424-LAC | 200 µl | $455.00 |
ADGRF5 encodes the adhesion G protein–coupled receptor GPR116, a membrane receptor implicated in cell–cell and cell–matrix signaling programs that shape epithelial and endothelial homeostasis. As an aGPCR, GPR116 can couple to heterotrimeric G proteins to influence second-messenger signaling and cytoskeletal dynamics, with reported roles in regulating barrier properties, inflammatory tone, and tissue remodeling. In the lung, GPR116 has been linked to surfactant regulation and alveolar stability, connecting receptor activity to pathways controlling lipid handling and epithelial function. Altered ADGRF5/GPR116 expression has been observed in contexts relevant to inflammation and cancer biology, supporting its use as a mechanistic node for studying GPCR-driven phenotypes in human cells.
GPR116 Lentiviral Activation Particles (h) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient ADGRF5 upregulation across a broader range of human cell types.
GPR116 Lentiviral Activation Particles (h) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the ADGRF5 transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous GPR116 expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native ADGRF5 genomic locus and regulatory architecture.
The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.